EVOTAZ 300 MG-150 MG TABLET

atazanavir and cobicistat
$51.9504per EA

Strength

300; 150 mg/1; mg/1

NDC

00003364111

Classification

Brand

Dosage Form

TABLET

Route

ORAL

Last Updated

4/22/2026

Approval Type

New Drug (NDA)

FDA Application

NDA206353

On Market Since

1/29/2015

Pharmacological Classes

Breast Cancer Resistance Protein Inhibitors
Cytochrome P450 2C8 Inhibitors
Cytochrome P450 2D6 Inhibitors
Cytochrome P450 3A Inhibitor
Cytochrome P450 3A Inhibitors
Cytochrome P450 3A Inhibitors
Cytochrome P450 3A4 Inhibitors
HIV Protease Inhibitors
Multidrug and Toxin Extrusion Transporter 1 Inhibitors
Organic Anion Transporting Polypeptide 1B1 Inhibitors
Organic Anion Transporting Polypeptide 1B3 Inhibitors
P-Glycoprotein Inhibitors
Protease Inhibitor
UDP Glucuronosyltransferases Inhibitors
UGT1A1 Inhibitors

Price History

1W

0.0%

1M

-0.1%

3M

+0.0%

6M

-0.1%

1Y

-0.2%

3Y

-0.3%

5Y

+0.0%

All

+15.3%

Generic Alternatives

No alternatives available

No alternatives found with the same active ingredient, strength, and dosage form.